Close menu




December 23rd, 2025 | 07:20 CET

Spectacular gains in 2025: Almonty up 8x, Rheinmetall up 2x - is TKMS next? Let profits run?

  • Mining
  • Tungsten
  • Defense
  • Investments
Photo credits: pixabay.com

Commodity stocks and defense shares were among investors' favorites in 2025. Rheinmetall shares have more than doubled this year and have even increased tenfold since the outbreak of the war between Russia and Ukraine. An especially impressive rally was delivered by Almonty Industries, whose share price rose eightfold. The signs continue to point to growth, as the Company has key unique selling points and significant geopolitical relevance in the supply of strategic metals that are urgently needed in the West and are essential for the defense industry and high-tech sector. The necessary security of supply is also attracting governments as buyers. The development of stock market newcomer TKMS is also exciting. The order books of the manufacturer of submarines and naval vessels are filling up. The motto for these stocks in 2026 is: stay on board.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: ALMONTY INDUSTRIES INC. | CA0203987072 , RHEINMETALL AG | DE0007030009 , TKMS AG & CO KGAA | DE000TKMS001

Table of contents:


    Almonty Industries – Full coffers for expansion

    Almonty is currently marking a decisive milestone. The Sangdong Mine in South Korea is about to finalize the commissioning of its processing operations. This will create the largest production facility for this highly sought-after strategic metal outside of China. The world-class deposit, with its exceptional quality and very long life, undoubtedly has geopolitical significance.

    The Sangdong Mine promises high profitability, as it was designed to be profitable even in a low-price environment. However, due to high demand and supply shortages, prices have been at a completely different level for some time now – far, far away from the low-price scenario. Everything, therefore, points to high margins.

    With the recent acquisition of an advanced tungsten project in the US state of Montana, Almonty has secured its presence in a key region. A particular advantage is that existing permits and good infrastructure will enable a rapid and capital-efficient start to production, which the Company has announced for the second half of 2026.

    In order to grow comfortably, Almonty recently carried out a capital increase with a volume of an impressive USD 129 million, which was in high demand and oversubscribed. This means that several new long-term institutional investors from the United States are now on board. The transaction, which was carried out at a price of USD 6.25 per share, was led by Bank of America. Almonty is already planning to relocate its headquarters to the US. As a logical step, Nasdaq will become the main stock exchange from January 1, 2026, but the listing on the Canadian stock exchange will be maintained.

    The growth prospects for the tungsten producer are enormous. High demand, rising prices, and sales volumes promise high profits in the future. The success of the latest capital increase reflects the great interest of institutional investors. With its Nasdaq listing, Almonty has a wide-reaching presence that should provide positive momentum for the stock.

    https://youtu.be/HwxJCF--kG8

    Rheinmetall – Rising order intake

    With a price increase of around 150% this year, the defense group's stock is the top performer in the German benchmark index. In the current fiscal year, Rheinmetall is targeting revenue of EUR 12.2 to 12.7 billion. The Company recently announced a target of EUR 50 billion for 2030, with rising margins. This contrasts with a current market capitalization of EUR 72 billion. Analysts predict an average upside potential of around 40% for the shares over the next 12 months.

    Geopolitical tensions and defense budgets at unprecedented levels are causing order books to grow. A prime example of this is the recent order for 200 armored personnel carriers and 84 wheeled howitzers from the German federal government with a volume of EUR 4.2 billion. In addition, the German Armed Forces placed an order worth around EUR 1.7 billion in the new space satellite business segment. Specifically, this involves access to space-based data provided by SAR satellites.

    Defense is the Group's core business, although it also operates in civilian business areas. Rheinmetall intends to divest its non-defense operations, which primarily comprise automotive supply and energy-related activities, and has stated that a separation is targeted in the course of 2026. According to the Company, negotiations are underway with two bidders. At the same time, Rheinmetall is expanding its core business through acquisitions. This year, for example, the purchase of NVL enabled it to expand its business activities into the marine sector.

    TKMS – Orders surged sixfold last year

    With its IPO, the marine specialist joined the public markets this year, offering an exciting growth story in the defense sector. The spin-off from thyssenkrupp Group, which retains a 51% majority stake, presented its figures for the past (interim) fiscal year at the beginning of the month.

    The figures and outlook were well received by analysts. Deutsche Bank experts raised their price target to EUR 82, which corresponds to an upside of 25%. In the period under review, revenue increased by 9% to EUR 2.2 billion, while operating profit grew at a significantly higher rate, with adjusted EBIT rising by 53% to EUR 131 million. The margin was 6% and is expected to rise to over 7% in the medium term.

    Free cash flow more than doubled compared to the previous year, reaching EUR 784 million. As part of the shareholder-friendly distribution policy, 30-50% of profits are to be distributed to investors as dividends. The order backlog grew by over 50% to EUR 18.2 billion, while new order intake surged sixfold, underscoring the Group's strong growth momentum.


    The conditions could hardly be better for Almonty. Several factors point to success: high demand, high prices, and high profitability. With Nasdaq, the stock also gains a high-reach platform. Rheinmetall is becoming a pure-play defense stock through the sale of its civilian business activities. Strong growth, including inorganic growth, is convincing. Margins will increase significantly as a result of the focus. TKMS was able to increase its order intake sixfold in the last fiscal year. The order backlog is over EUR 18 billion. In contrast, the Company is valued at around EUR 4 billion.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Tarik Dede on October 15th, 2026 | 05:35 CEST

    Opportunities and Risks: ASML, Almonty Industries and Lynas Rare Earths in Focus

    • ASML
    • EUV lithography system
    • Lynas Rare Earths
    • Rare earths
    • Almonty Industries
    • Tungsten

    Whether driven by interest rate concerns, geopolitical tensions or high oil prices, making money in the market is no easy task right now. In times like these, it is important to focus on the operational performance of individual companies. Businesses that deliver solid profit growth and prove resilient in the face of market headwinds may be better positioned to navigate a difficult environment. Meanwhile, the ongoing euphoria around artificial intelligence may be nearing the end of the boom. Analysts estimate that around 3% of US GDP is now flowing into the AI industry alone. This would make the current boom even larger than the stock market frenzy surrounding railway shares in the 19th century. Today, we take a closer look at ASML and examine the opportunities and risks facing Almonty Industries and Lynas Rare Earths.

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read